ArticleCancer cell international2026
FGD3 as a prognostic and immunological biomarker: a pan-cancer analysis of its role in tumor progression and the immune landscape.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFGD3, a member of the FGD family, regulates GTPase activity and cellular morphology, thereby influencing tumor proliferation and migration. However, its role across diverse cancer types remains insufficiently understood.
methodsUsing TCGA and GTEx databases, FGD3 expression was compared between tumor and normal tissues to assess its relevance to cancer. Single-cell transcriptomic data from TISCH were used to characterize FGD3 expression across immune cell subsets. Univariate Cox regression was performed to evaluate associations between FGD3 expression and patient survival. TIMER2.0 Spearman correlation analysis examined its relationship with immune cell infiltration. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) revealed FGD3's association with immune and metabolic pathways. Bioinformatics and molecular docking predicted interactions with anticancer drugs. Experimental validation demonstrated that FGD3 knockdown suppresses cancer cell migration and proliferation, indicating an anti-tumor role in breast cancer.
resultsFGD3 expression varies across tumors, with differing prognostic implications. In most malignancies, expression inversely correlates with copy number variation (CNV) and methylation and associates with immunotherapy biomarkers and responses. ESTIMATE and immune infiltration analyses suggest a role in immunosuppression and tumor immunity. Experimental downregulation of FGD3 significantly reduces cell proliferation and migration, highlighting its therapeutic potential.
conclusionFGD3 plays an important role in tumorigenesis and progression and may serve as a promising biomarker for cancer prognosis. Its expression is inversely associated with tumor metastasis. Experimental findings further suggest that FGD3 may function as a migration-suppressive factor in breast cancer. Collectively, these results provide new insights into the biological role of FGD3 and suggest its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.